Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: EP Technologies

This article was originally published in The Gray Sheet

Executive Summary

EP Technologies: Radiofrequency ablation device firm announces Oct. 6 that it is "in discussions with respect to a possible business combination at a price of $13 per share." The price would give the deal a value of roughly $150 mil., about six times EP Technologies' current revenues, but it would represent a discount to the $16 per share closing price of the company's stock on Oct. 5. EPT stock has gained value recently on takeover speculation. EPT is one of two firms -- the other is Medtronic -- with FDA approval for an RF ablation system for treatment of tachyarrhythmias. Potential buyers could include Boston Scientific, St. Jude, and Johnson & Johnson...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004818

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel